Acorai closes $4.5M investment from the European Innovation Council (EIC) Fund
Acorai, a Swedish developer and manufacturer of innovative devices for heart failure management, announced the closing of a $4.5M investment from the EIC Fund, Taiwan Medical University, and private investors. The capital will be used to complete Acorai’s clinical studies and prepare for regulatory submissions in the US and Europe. Patient enrollment for Acorai’s flagship clinical study, the CAPTURE-HF study, has been completed successfully, with over 1600 patients across 20 hospitals and 6 countries. With its FDA Breakthrough Device Designation in place and working closely with the FDA through the TAP Pilot, Acorai targets regulatory submissions and commercial launch by 2026. With an additional $6M provisioned from the EIC Fund for future equity financing, Acorai is preparing to raise additional capital in 2025 to fund further clinical validation, regulatory approvals and early commercialisation.
